August 16th 2025
Oncology nurses play a key role in monitoring, managing, and personalizing CDK4/6 inhibitor treatment to minimize toxicities and protect quality of life, according to Courtney Moore, APRN, FNP-C, OCN.
The HER2-Positive Metastatic Breast Cancer Landscape Could Gain a New Combination Treatment
September 12th 2019Treating patients with HER2-positive metastatic breast cancer is difficult, and patients can fail multiple lines of direct treatment. But now, the FDA has accepted a supplemental new drug application for a combination treatment to help these patients failing multiple treatments.
Patient Navigation Project Builds Foundation to Improve Breast Cancer Outcomes
June 27th 2019With a goal of championing the value of patient navigators, Susan G. Komen Greater New York City and NYU Langone have teamed up to provide patients with improved care in Brooklyn through a new patient navigation project.
FDA Approves Trastuzumab-Anns, a Herceptin Biosimilar
June 14th 2019The Food and Drug Administration (FDA) approved trastuzumab-anns (Kajinti), a biosimilar of trastuzumab (Herceptin) for the treatment of HER2-overexpressing breast cancer, metastatic gastric or gastroesophageal junction adenocarcinoma.